9:07 AM ET
8-K
M&A Deal
Jazz Pharmaceuticals Signs $820M M&A Deal with Actio Biosciences, Inc.
Jazz Pharmaceuticals completed its acquisition of Actio Biosciences for $820 million upfront, making Actio a wholly-owned subsidiary. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, to Jazz's rare disease and epilepsy pipeline. As part of the transaction, Actio spun out its non-ABS-1230 programs into a new private entity in which Jazz retains a minority stake.
- Value
- $820M
- Counterparty
- Actio Biosciences, Inc.